Recent Analysts’ Ratings Updates for Kymera Therapeutics (KYMR)

Several brokerages have updated their recommendations and price targets on shares of Kymera Therapeutics (NASDAQ: KYMR) in the last few weeks:

• 6/30/2026 – Kymera Therapeutics had its price target raised by Bank of America Corporation from $110.00 to $125.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Kymera Therapeutics had its price target raised by B. Riley Financial, Inc. from $117.00 to $155.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Kymera Therapeutics had its price target raised by Truist Financial Corporation from $116.00 to $136.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Kymera Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $106.00 to $129.00. They now have a “buy” rating on the stock.
• 6/25/2026 – Kymera Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $134.00 price target on the stock.
• 6/8/2026 – Kymera Therapeutics was given a new $97.00 price target by Loop Capital.
• 6/8/2026 – Kymera Therapeutics had its “buy” rating reaffirmed by Brookline Capital Markets.

Insider Buying and Selling

In other news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the firm’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $106.50, for a total value of $168,142,200.00. Following the sale, the director directly owned 240,123 shares in the company, valued at approximately $25,573,099.50. This trade represents a 86.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Noah Goodman sold 3,389 shares of Kymera Therapeutics stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $114.29, for a total transaction of $387,328.81. Following the sale, the insider directly owned 47,179 shares of the company’s stock, valued at approximately $5,392,087.91. This trade represents a 6.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 3,621,769 shares of company stock worth $387,333,335. Corporate insiders own 15.98% of the company’s stock.

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.